Publications

2018

International consensus on quality standards for brain health-focused care in multiple sclerosis.
Hobart J, Boyko A, Boz C, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.
Mult Scler. Nov 1, 2018 

 

Digestive side-effects with teriflunomide: Thoughts on lactose.
Lebrun C, Bertagna M, Bresch S, Cohen M. 
Rev Neurol (Paris). 2018

 

De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Panicucci E, Cohen M, Bourg V, Rocher F, Thomas P, Lebrun C
Mult Scler. 2018

 

Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.
Lebrun C, Rocher F.
CNS Drugs. 2018 Aug 24. doi: 10.1007/s40263-018-0564-y.

 

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques.
J Neurol. 2018 Jul 27. doi: 10.1007/s00415-018-8984-7.

 

Demyelinating diseases.
Lebrun C, de Seze J.
Rev Neurol (Paris). 2018 Jun;174(6):355. doi: 10.1016/j.neurol.2018.04.007.

 

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?
Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S.
Eur Radiol. 2018 Jun 19. doi: 10.1007/s00330-018-5543-7.

 

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.
Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.
CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

 

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.
Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560.

 

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.
Lebrun C, Cohen M, Rosenthal-Allieri MA, Bresch S, Benzaken S, Marignier R, Seitz-Polski B, Ticchioni M.
Neurol Ther. 2018 Jun 7. doi: 10.1007/s40120-018-0101-4. 

 

Should we treat patients with radiologically isolated syndrome (RIS)? Comments.
Lebrun C.
Rev Neurol (Paris). 2018 May 17. pii: S0035-3787(18)30612-X. doi: 10.1016/j.neurol.2018.02.085. 

 

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.
Lancet Neurol. 2018 Mar 12. pii: S1474-4422(18)30069-3.

 

Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
Thouvenot E, Hinsinger G, Demattei C, Uygunoglu U, Castelnovo G, Pittion-Vouyovitch S, Okuda D, Kantarci O, Pelletier D, Lehmann S, Marin P, Siva A, Lebrun C; SFSEP and RISC.
Mult Scler. 2018 Mar 1:1352458518767043. 

 

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R; Francophone Society of Multiple Sclerosis and OFSEP investigators.
J Neurol. 2018 Feb 17. doi: 10.1007/s00415-018-8771-5. 

 

Psychological processes associated with insomnia in patients with multiple sclerosis.
Schellaert V, Labauge P, Lebrun C, Maudarbocus KH, Bernard J, Blache JB, Ayrignac X, Carra-Dallière C, Gély-Nargeot MC, Bayard S.
Sleep. 2018 Jan 4.

 

Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome.
Lebrun C, Kantarci OH, Siva A, Pelletier D, Okuda DT; RISConsortium.
Neurol Clin. 2018 Feb;36(1):59-68. 

 

Cervical spinal cord atrophy: An early marker of progressive MS onset.
Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, Pelletier D, Azevedo CJ, Lebrun-Frenay C, Siva A, Okuda DT, Kantarci K, Kantarci OH.
Neurol Neuroimmunol Neuroinflamm. 2018 Jan 22;5(2):e435.

 

Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P.
PLoS One. 2017 Nov 27;12(11):e0188120. doi: 10.1371/journal.pone.0188120. eCollection 2017.

 

Multiple sclerosis treatments and the anti-JCV antibody index.
de Seze J, Lebrun-Frenay C;
Rev Neurol (Paris). 2017 Dec;173(10):e1. doi: 10.1016/j.neurol.2017.09.008. Epub 2017 Nov 2. No abstract available.

 

2017

Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.
Moisset X, Perié M, Pereira B, Dumont E, Lebrun-Frenay C, Lesage FX, Dutheil F, Taithe F, Clavelou P.
PLoS One. 2017 Nov 27;12(11):e0188120. 

 

Multiple sclerosis treatments and the anti-JCV antibody index. 
de Seze J, Lebrun-Frenay C.
Rev Neurol (Paris). 2017 Nov 2. pii: S0035-3787(17)30735-X. 

 

Anomalies Characteristic of Central Nervous System Demyelination: Radiologically Isolated Syndrome.
Lebrun C, Kantarci OH, Siva A, Pelletier D, Okuda DT; RISConsortium.
Neurol Clin. 2018 Feb;36(1):59-68. 

 

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it? 
Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaques, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.
Mult Scler Relat Disord. 2017 Nov;18:161-163. 

 

Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.
Cohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C; Qualicis Study Group.
J Neurol Sci. 2017 Nov 15;382:73-78. 

 

Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. 
Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.
Neurology. 2017 Feb 7;88(6):514-524. 

 

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.
Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.
Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. 

 

Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.
Ann Neurol. 2017 Jul;82(1):20-29. 

 

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. 
Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.
Ann Neurol. 2017 Aug;82(2):186-195. 

 

A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. 
Lebrun C, Cohen M, Mondot L, Ayrignac X, Labauge P.
Neurol Ther. 2017 Aug 24. 

 

Radiologically isolated syndrome in children: Clinical and radiologic outcomes. 
Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D.
Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e395. 

 

Radiologically isolated syndrome should be treated with disease-modifying therapy - Commentary. 
Lebrun C.
Mult Scler. 2017 Sep 1:1352458517727149. 

 

New insights into the burden and costs of multiple sclerosis in Europe: Results for France. 
Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M; European Multiple Sclerosis Platform.
Mult Scler. 2017 Aug;23(2_suppl):65-77. 

 

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G.
Eur J Endocrinol. 2017 Jun;176(6):769-777. 

 

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). 
Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M.
Heliyon. 2017 Feb 13;3(2):e00245. 

 

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. 
Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L; PGRx-AD Study Group.
J Autoimmun. 2017 May;79:84-90. 

 

Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.
 Do LD, Chanson E, Desestret V, Joubert B, Ducray F, Brugière S, Couté Y, Formaglio M, Rogemond V, Thomas-Antérion C, Borrega L, Laurens B, Tison F, Curot J, De Brouker T, Lebrun-Frenay C, Delattre JY, Antoine JC, Honnorat J.
Neurology. 2017 Feb 7;88(6):514-524.

 

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. 
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.
N Engl J Med. 2017 Jan 19;376(3):209-220. 

 

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M, DeSalvador F, Harvey-Langton A, Dunais B, Laffon M, Cottalorda J, Dellamonica P, Pradier C.
J Neurovirol. 2017 Apr;23(2):216-225. 

 

Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS? 
Van Obberghen EK, Cohen M, Rocher F, Lebrun-Frenay C.
Rev Neurol (Paris). 2017 Apr;173(4):222-224.

 

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.
Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.
Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. 

 

Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. 
Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, Brunet C, Rico A, Pelletier J, Audoin B, Lebrun C.
J Neurol Sci. 2017 Feb 15;373:335-338. 

 

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators.
PLoS One. 2017 Jan 3;12(1):e0168834

 


Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
Lebrun C, Bourg V, Bresch S, Cohen M, Rosenthal-Allieri MA, Desnuelle C, Ticchioni M.
J Neuroimmunol. 2016 Sep 15;298:79-81. doi: 10.1016/j.jneuroim.2016.07.009. Epub 2016 Jul 11. 

 

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network; RISC.
J Neurol Sci. 2016 Sep 15;368:334-6. 

 

Evaluation of quality of life and fatigue in radiologically isolated syndrome.
Lebrun C, Cohen M, Clavelou P; SFSEP.
Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):392-5. doi: 10.1016/j.neurol.2016.04.004. Epub 2016 May 2.

 

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.
Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4

 

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.
J Neurol Sci. 2016 Apr 15;363:69-76.

 

Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab.
Romero G, Ticchioni M, Cohen M, Rosenthal-Allieri MA, Mondot L, Lebrun Frenay C.
Rev Neurol (Paris). 2016 Mar;172(3):220-4. doi: 10.1016/j.neurol.2015.12.004. Epub 2016 Feb 23. Review.

 

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.
Neurology. 2016 Mar 8;86(10):920-30. 

 

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.
Neurology. 2016 Feb 23;86(8):771-8

 

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.
Neurology. 2016 Sep 6;87(10):978-87. 

 

2016

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M, DeSalvador F, Harvey-Langton A, Dunais B, Laffon M, Cottalorda J, Dellamonica P, Pradier C.
J Neurovirol. 2016 Nov 4. [Epub ahead of print]

 

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks..
Neurology. 2016 Nov 4. pii: 10.1212/WNL.0000000000003401. [Epub ahead of print] 

 

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.
Mult Scler. 2016 Nov;22(13):1719-1731.

 

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.
Neurology. 2016 Sep 6;87(10):978-87. 

 

Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
Lebrun C, Bourg V, Bresch S, Cohen M, Rosenthal-Allieri MA, Desnuelle C, Ticchioni M.
J Neuroimmunol. 2016 Sep 15;298:79-81. 

 

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.
Papeix C1, Vukusic S1, Casey R1, Debard N1, Stankoff B1, Mrejen S1, Uhry Z1, Van Ganse E1, Castot A1, Clanet M1, Lubetzki C1, Confavreux C1; TYSEDMUS and OFSEP Group.
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016.

 

Determinants of treatment persistence with glatiramer acetate in the French national Copaxone registry.
C Lebrun-Frenay,  A Moulignier, C Pierrot-Deseilligny, T Moreau, B Salin, F Monchecourt
ECTRIMS Online Library. Sep 15, 2016; 146528

 

Multi-center, randomized, double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) (TERIS study).
C Lebrun, A Siva, O Kantarci, C Azevedo, M.P Sormani, D Pelletier, D Okuda,
RISC ECTRIMS Online Library. C. Sep 14, 2016; 145587

 

Radiologically Isolated Syndrome: Pathologically Defined as Demyelinating Disease
M Keegan, Y Guo, D Okuda, A Siva, D Pelletier, O Kantarci, C Lucchinetti, C Lebrun Frenay.
P1.391 - AAN Meeting 2016, Vancouver

 

Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data
F Nelson, C Lebrun-Frenay, W Camu, A Boyko, K Thangavelu, P Rufi, S Cavalier, P Truffinet, J Liang, F Lublin.
P3.038 - AAN Meeting 2016, Vancouver

 

Pediatric Radiologically Isolated Syndrome: Clinical and Radiological Outcomes
N Makhani, C Lebrun Frenay, A Siva, C Carra-Dalliere, J De Seze, F Durand Dubief, O Kantarci, M Langille, J Pelletier, J Rojas, T Schreiner, MTintore, U Uygunoglu, D Okuda, D Pelletier, Observatoire Francophone de la Sclérose en Plaques (OFSEP), Société Francophone de la Sclérose en Plaques (SFSEP), Radiologically Isolated Syndrome.
S29.002 - AAN Meeting 2016, Vancouver

 

Therapeutic Target of Memory B Cells Depletion Helps to Tailor Administration Frequency of Rituximab in Neuromyelitis Optica Spectrum
Disorders Patients C Lebrun Frenay, M Cohen, G Romero, A Rosenthal-Allieri, M Ticchioni.
P5.310 - AAN Meeting 2016, Vancouver

 

Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study
A Tourbah, C Arndt, A Vighetto, V Deburghgraeve, J Pelletier, C Papeix, C Lebrun-Frenay, P Labauge, M Clanet, AToosy, D Laplaud, P Vermersch, T Moreau, M Debouverie, P Clavelou, O Heinzlef, J De Seze, G Defer, F Sedel, O Gout.
S49.005 – AAN Meeting 2016, Vancouver

 

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network; RISC.
J Neurol Sci. 2016 Sep 15;368:334-6. 

 

Evaluation of quality of life and fatigue in radiologically isolated syndrome.
Lebrun C, Cohen M, Clavelou P; SFSEP.
Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):392-5. 

 

Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study.
Berna F, Blanc F, Lebrun C, Castelnovo G, Clerc C, Debouverie M, Jouvenoz D, Marcel-Viallet M, Zaenker C, Zephir H, Vidailhet P, De Sèze J.
Mult Scler Relat Disord. 2016 Mar;6:93-6. 

 

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.
Cohen M, De Sèze J, Marignier R, Lebrun C.
Mult Scler. 2016 Aug;22(9):1231-4. 

 

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.
Neurology. 2016 Feb 23;86(8):771-8. 

 

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.
Mult Scler. 2016 Sep 1. pii: 1352458516667568. [Epub ahead of print]

 

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.
Neurology. 2016 Sep 6;87(10):978-87. 

 

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
P Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.
J Neurol Sci. 2016 Apr 15;363:69-76. 

 

Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab.
Romero G, Ticchioni M, Cohen M, Rosenthal-Allieri MA, Mondot L, Lebrun Frenay C.
Rev Neurol (Paris). 2016 Mar;172(3):220-4. 

 

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.
Neurology. 2016 Mar 8;86(10):920-30. 

 

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. 
Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.
Neurology. 2016 Feb 23;86(8):771-8. 

 

Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT.
Ann Neurol. 2016 Feb;79(2):288-94. 

 

2015

Results from a randomized double-blind crossover study comparing oral L-carnitine versus placebo and a subsequent physical rehabilitation program for the treatment of fatigue in multiple sclerosis.
J Ouallet, J Asselineau, D Laplaud, S Wiertlewski, S Pittion, M Debouverie, C Lebrun Frenay, M Cohen, P Cabre, S Jeannin, G Chene, D Brassat, A Saubusse, D Djigo, J Chateauraynaud, B Brochet.
[P1.125]. AAN Meeting 2015, Washington

 

Are individuals with Radiologically Isolated Syndrome have a different clinical outcome once they convert to Clinically Isolated Syndrome?
A Siva, M Tutuncu, O Kantarci, U Uygunoglu, P Acar, A Kurne, M Keegan, A Altintas, S Saipoglu, R Karabudak, D Pelletier, D Okuda, C Lebrun Frenay, for Radiologically Isolated Syndrome Consortium (RISC), Club Francophone de la Sclérose en Plaques (CFSEP).
[P5.193]. AAN Meeting 2015, Washington.

 

Rituximab as First-Line Therapy in Neuromyelitis Optica: Efficiency and Tolerability
R Bernard-Valnet, C Lebrun Frenay, B Audoin, B Bourre, S Pittion, S Wiertlewski, R Marignier, J Ciron, B Brochet, D Brassat, H Zephir, NOMADMUS, CFSEP.
[P5.258] AAN Meeting 2015, Washington

 

Multi-center, randomized, double-blinded assessment of dimethyl fumarate in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE Trial).
D Okuda, C Lebrun Frenay, A Siva, C Hotermans, C Von Hehn, G Remington, B Newton, T Frohman, E Frohman, O Kantarci, D Pelletier.
[P7.207] AAN Meeting 2015, Washington

 

The radiologically isolated syndrome.
Lebrun C.
Rev Neurol (Paris). 2015 Oct;171(10):698-706.

 

Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G; COPOUSEP investigators; West Network for Excellence in Neuroscience.
Lancet. 2015 Sep 5;386(9997):974-81. 

 

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.
J Neurol. 2015 Oct;262(10):2329-35. 

 

A breakthrough for the treatment of spasticity in multiple sclerosis.
Lebrun C, Vermersch P.
Rev Neurol (Paris). 2015 Apr;171(4):327-8. 

 

Solitary sclerosis: Experience from three French tertiary care centres.
Cohen M, Lebrun C, Ayrignac X, Labauge P, Assouad R.
Mult Scler. 2015 Aug;21(9):1216. 

 

Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome.
Lebrun C, Forzy G, Collongues N, Cohen M, de Seze J, Hautecoeur P; Club francophone de la SEP and RISConsortium.
Rev Neurol (Paris). 2015 Apr;171(4):390-3. 

 

Endocanabinoids : Country break-out session highlights.
Fazekas F, Gehring K, Gallo P, Lebrun-Frénay C, Moral E, Myhr KM.
Neurodegener Dis Manag. 2015;5(6 Suppl):31-7. 

 

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.
Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.
PLoS One. 2015 Jul 6;10(7):e0132033. 

 

Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C.
HIV Med. 2015 Aug;16(7):431-40. 

 

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.
J Neurol. 2015 Jul;262(7):1637-45. 

 

Early CNS neurodegeneration in radiologically isolated syndrome.
Azevedo CJ, Overton E, Khadka S, Buckley J, Liu S, Sampat M, Kantarci O, Lebrun Frenay C, Siva A, Okuda DT, Pelletier D.
Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e102. 

 

High doses of biotin in chronic progressive multiple sclerosis: a pilot study.
Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A.
Mult Scler Relat Disord. 2015 Mar;4(2):159-69. 

 

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.
Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.
Brain. 2015 Feb;138(Pt 2):284-92. 

 

Actualités

Comment accéder au centre ?

Hopital Pasteur, service de Neurologie
30 Voie Romaine
06000 Nice

  • Par la route
    Sortie Nice-Est puis suivre Hôpital Pasteur
  • Par le tramway
    Ligne 1, vers Hôpital Pasteur, arrêt Hôpital Pasteur (terminus)
  • Par le bus
    Ligne 8, vers Pasteur, arrêt Hôpital Pasteur
  • Où se garer ?
    Le 3ème sous sol du parking de l'hôpital est réservé au public.

Conformément à la législation relative à la protection des données, nous vous informons que ce site utilise des cookies à des fins de statistiques. En cliquant sur le bouton 'Accepter', vous autorisez les services tiers que nous utilisons à éventuellement déposer un ou plusieurs cookies sur votre ordinateur. Pour en savoir plus, consultez nos mentions légales